Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST). Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistancemutations inKIT,with those located in the activation (A) loop (exons 17/ 18) being particularly problematic. Here, we explore the KIT-inhibitory activity of ponat...

Abstract Introduction Following the results from REGOMA study, regorafenib has become first chemotherapeutic option for recurrent glioblastoma, IDH-wildtype, in many countries. However, predictive factors response to are scarcely recognized. The objective of this study was identify molecular using a clinically available platform. METHODS We analyzed prospective cohort 30 patients harboring and ...

The RAS/RAF/MEK/MAPK and the PTEN/PI3K/AKT/mTOR pathways are key regulators of proliferation and survival in human cancer cells. Selective inhibitors of different transducer molecules in these pathways have been developed as molecular targeted anti-cancer therapies. The in vitro and in vivo anti-tumor activity of pimasertib, a selective MEK 1/2 inhibitor, alone or in combination with a PI3K inh...